UnitedHealth beat fourth-quarter earnings forecast, though revenue fell short and medical costs ran high, hitting the Dow ...

Backers of China's Xiaohongshu are looking to sell a part of their stake to the likes of Tencent, among others, in a deal ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

The brand-name versions, from drugmaker Novo Nordisk ... an advocacy group that tracks counterfeit drugs, said fake GLP-1 medications are “the No. 1 fraud issue” that group is seeing in ...

Four heads of iconic U.S. enterprises face turbulent, inherited challenges with elevated investor anxiety in 2025.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Diabetes and weight-loss medications, known as GLP-1 or incretin drugs, have taken the world by storm — especially the United ...